ChiCTR2600117039 版本V1.0 版本创建时间2026/01/19 14:30:39 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600117039 

最近更新日期:

Date of Last Refreshed on:

2026-01-19 14:30:31 

注册时间:

Date of Registration:

2026-01-19 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

孤独症谱系障碍与注意缺陷多动障碍的感觉统合能力多维对比及相关性研究

Public title:

Multidimensional comparison and correlation of sensory integration ability between autism spectrum disorder and attention deficit hyperactivity disorder

注册题目简写:

English Acronym:

研究课题的正式科学名称:

孤独症谱系障碍与注意缺陷多动障碍的感觉统合能力多维对比及相关性研究

Scientific title:

Multidimensional comparison and correlation of sensory integration ability between autism spectrum disorder and attention deficit hyperactivity disorder

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈宇希 

研究负责人:

代英 

Applicant:

Chen Yuxi 

Study leader:

Dai Ying 

申请注册联系人电话:

Applicant telephone:

+86 23 6837 0551

研究负责人电话:

Study leader's telephone:

+86 23 6837 0551

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

c2h41998@163.com

研究负责人电子邮件:

Study leader's E-mail:

dai@hospital.cqmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区中山二路136号

研究负责人通讯地址:

重庆市渝中区中山二路136号

Applicant address:

No. 136, Zhongshan Second Road, Yuzhong District, Chongqing

Study leader's address:

No. 136, Zhongshan Second Road, Yuzhong District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆医科大学附属儿童医院

Applicant's institution:

Children's Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属儿童医院

Affiliation of the Leader:

Children's Hospital of Chongqing Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2025)年伦审(临研)第(313)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属儿童医院医学研究伦理委员会

Name of the ethic committee:

Institutional Review Board Children's Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-07-18 00:00:00

伦理委员会联系人:

蔡诗容

Contact Name of the ethic committee:

Cai Shirong

伦理委员会联系地址:

重庆市渝中区中山二路136号

Contact Address of the ethic committee:

No. 136, Zhongshan Second Road, Yuzhong District, Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 68370035

伦理委员会联系人邮箱:

Contact email of the ethic committee:

741223671@qq.com

研究实施负责(组长)单位:

重庆医科大学附属儿童医院

Primary sponsor:

Children's Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区中山二路136号

Primary sponsor's address:

No. 136, Zhongshan Second Road, Yuzhong District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属儿童医院

具体地址:

重庆市渝中区中山二路136号

Institution
hospital:

Children's Hospital of Chongqing Medical University

Address:

No. 136, Zhongshan Second Road, Yuzhong District, Chongqing

经费或物资来源:

自筹

Source(s) of funding:

raise independently

Target disease:

Autism spectrum disorder, attention deficit hyperactivity disorder

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

拟采用公认的感觉统合核检表对ASD、ADHD及其共病儿童进行多维度评估,比较三组儿童在不同维度的感觉统合能力的差异,研究其感觉统合异常的特征性表现,探索感觉统合异常与ASD、ADHD的核心症状的关联性,为临床早期识别提供线索。  

Objectives of Study:

It is planned to use the recognized sensory integration checklist to carry out multi-dimensional evaluation on children with ASD, ADHD and their comorbidities, compare the differences of sensory integration abilities of the three groups of children in different dimensions, study the characteristic manifestations of sensory integration abnormalities, explore the correlation between sensory integration abnormalities and the core symptoms of ASD and ADHD, and provide clues for early clinical recognition.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.ASD儿童:年龄在6-12岁,经行为发育医师评估有发育异常表现,符合美国精神障碍诊断统计手册第5版(DSM-5)关于ASD的诊断标准,结合ADOS、CARS、SRS、ABC、M-CHAT等确诊ASD; 2.ADHD儿童:年龄在6-12岁,经行为发育医师评估有发育异常表现,符合DSM-5关于ADHD的诊断标准,结合Vanderbilt量表、儿童困难问卷等确诊ADHD; 3.ASD及ADHD共病儿童:年龄在6-12岁,经行为发育医师评估有发育异常表现,同时符合DSM-5关于ASD及ADHD的诊断标准,结合ADOS、CARS、SRS、ABC、M-CHAT、Vanderbilt量表、儿童困难问卷等确诊ASD共患ADHD.

Inclusion criteria

1. Children with ASD: Aged 6-12 years, showing developmental abnormalities as assessed by a behavioral development physician, meeting the DSM-5 diagnostic criteria for ASD, and confirmed with tools such as ADOS, CARS, SRS, ABC, and M-CHAT; 2. Children with ADHD: Aged 6-12 years, showing developmental abnormalities as assessed by a behavioral development physician, meeting the DSM-5 diagnostic criteria for ADHD, and confirmed with tools such as the Vanderbilt scale and the Child Difficulty Questionnaire; 3. Children with comorbid ASD and ADHD: Aged 6-12 years, showing developmental abnormalities as assessed by a behavioral development physician, meeting the DSM-5 diagnostic criteria for both ASD and ADHD, and confirmed with tools such as ADOS, CARS, SRS, ABC, M-CHAT, Vanderbilt scale, and the Child Difficulty Questionnaire.

排除标准:

1.其他已知的严重神经精神疾病,染色体、遗传代谢性疾病及其他重大躯体疾病,如视听障碍、癫痫、苯丙酮尿症、结节性硬化、神经纤维瘤、严重脑外伤等疾病; 2.监护人不愿参与研究者。

Exclusion criteria:

1. Other known severe neuropsychiatric disorders, chromosomal, genetic metabolic diseases, and other major physical diseases, such as visual and auditory impairments, epilepsy, phenylketonuria, tuberous sclerosis, neurofibromatosis, severe traumatic brain injury, etc.; 2. Guardians unwilling to participate in the study.

研究实施时间:

Study execute time:

From 2025-08-01 00:00:00 To 2026-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-08-01 00:00:00 To 2026-06-01 00:00:00  

干预措施:

Interventions:

组别:

ASD+ADHD组

样本量:

43

Group:

ASD+ADHDgroup

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

ADHD组

样本量:

43

Group:

ADHD group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

ASD组

样本量:

43

Group:

ASD group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China 

Province:

Chongqing 

City:

 

单位(医院):

重庆医科大学附属儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Children's Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

感觉统合检核表评分

指标类型:

主要指标

Outcome:

Sensory integration checklist score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

DOS、CARS、SRS、ABC、M-CHAT、VanderbiIt量表、儿童困难问卷等结果与儿童感觉统合检核表的相关系数

指标类型:

次要指标

Outcome:

Correlation coefficients between the results of DOS, CARS, SRS, ABC, M-CHAT, Vanderbilt scale, Children's Difficulties Questionnaire, and the Child Sensory Integration Checklist

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 6 years
最大 Max age 12 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

邮件联系研究者

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact the researcher by email

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-01-19 14:30:31